Advertisement

IP Issues in the Therapeutic Antibody Industry

  • Ulrich StorzEmail author
Protocol
Part of the Springer Protocols Handbooks book series (SPH)

Abstract

The following section is related to IP issues in the therapeutic Antibody industry. A rough overview over protected enabling techniques and compounds is provided, in order to facilitate the entry into freedom to operate studies. Furthermore, some general information about specific issues is provided, and the stories of some historic lawsuits fought between Antibody companies in the past are being told.

Keywords

Intellectual Property European Patent Office Patent Family Antibody Library Patent Infringement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Fürniss (1992) Festschrift für Nirk, CH Beck 1992, 305 ffGoogle Scholar
  2. Hosse RJ et al (2006) A new generation of protein display scaffolds for molecular recognition. Protein Sci 15:14PubMedCrossRefGoogle Scholar
  3. Kaufman RJ et al (1985) Coamplification and coexpression of human tissue-type plasminogen activator and murine dihydrofolate reductase sequences in CHO cells. Mol. Cell. Biol. 5:1750–1759PubMedGoogle Scholar
  4. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497PubMedCrossRefGoogle Scholar
  5. Lu DL et al (2007) The patentability of antibodies in the United States. Nat Biotechnol 23:1079–1108CrossRefGoogle Scholar
  6. Maglione D et al (1991) Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88:9267PubMedCrossRefGoogle Scholar
  7. Raftery J et al (2007) Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 91:1244–1246PubMedCrossRefGoogle Scholar
  8. Reuter C et al (2007) Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 96:408–416PubMedCrossRefGoogle Scholar
  9. Saklatvala J (1986) Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322:547–549PubMedCrossRefGoogle Scholar
  10. Skerra A (2007) Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 18(4):295PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Michalski Hüttermann & Partner Patent AttorneysDüsseldorfGermany

Personalised recommendations